Skip to main
INKT

MiNK Therapeutics (INKT) Stock Forecast & Price Target

MiNK Therapeutics (INKT) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiNK Therapeutics is seen as a strong buy with a projected price target of $35 based on its promising allogeneic, off-the-shelf, native iNKT cell therapy agenT-797 and its potential in treating cancer and other immune-mediated diseases. While there are inherent risks in the development and commercialization of novel therapies, the company's strong technology platform, current pipeline assets, and indications show potential for success and growth in the biopharmaceutical industry. MiNK may face challenges such as safety concerns and competition, but its current financial position and potential for continued financing suggest a bright future for the company.

Bears say

MiNK Therapeutics is a clinical-stage biopharmaceutical company with a negative stock outlook due to its heavy reliance on external capital and lack of FDA-approved therapies. While their agenT-797 shows promise in treating pneumonia and GvHD, the company's Phase 2 trials are not expected to yield results until 2H26. In addition, the company has no formal collaborations or agreements in place. Their highly-anticipated external GvHD trial is not expected to begin dosing until 2H26, which could negatively impact investor confidence.

MiNK Therapeutics (INKT) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiNK Therapeutics (INKT) Forecast

Analysts have given MiNK Therapeutics (INKT) a Strong Buy based on their latest research and market trends.

According to 1 analysts, MiNK Therapeutics (INKT) has a Strong Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiNK Therapeutics (INKT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.